EXAC Exactech, Inc.

Exactech Introduces New Computer-Assisted Software Application for Simplified Guidance in Total Knee Replacement

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced the introduction of ExactechGPS® TKA PLUS, a new software application that provides orthopaedic surgeons simplified, real-time intraoperative computer guidance during total knee arthroplasty (TKA). The new application expands the ExactechGPS portfolio and complements the company’s new Truliant® Knee System which is also making its clinical debut this quarter.

Derek Amanatullah, MD, PhD, performed the first surgery using ExactechGPS TKA PLUS at Stanford University Medical Center. “I was delighted to experience how seamlessly the system integrated into my surgical workflow,” he reported. “ExactechGPS TKA PLUS allowed me to use simple guidance to achieve precision and accuracy in my cuts, which made the knee replacement case run smoothly. I believe this system is exactly what surgeons need to help them achieve more reproducible outcomes.”

ExactechGPS is a computer technology system for guided, personalized joint replacement surgery. The new TKA PLUS software application provides surgeons a simple tool to plan, guide and verify key steps of a knee replacement procedure and easily check the patient’s implant alignment. This new application expands the ExactechGPS knee software portfolio, which also includes comprehensive applications for both primary and revision knee surgery.

“The launch of TKA PLUS reiterates Exactech’s commitment to delivering a fully comprehensive knee system to the marketplace,” said Joseph Pizzurro, vice president of Knee Marketing at Exactech. “The Truliant system of new implants and instruments, combined with our ExactechGPS technology, offers orthopaedic surgeons versatility in managing total knee arthroplasty cases from primary through revision. We are encouraged by the positive responses we have received and look forward to continued momentum behind our new knee system.”

ExactechGPS has been used in more than 8,500 total knee cases in 12 countries across the globe. ExactechGPS TKA PLUS is available in pilot launch, with full availability expected in 2018.

About ExactechGPS

ExactechGPS combines surgeon expertise with an advanced computer system to perform the patient’s surgery with a goal of improved accuracy and precision. Personalized for a patient’s unique bone structure and anatomy, ExactechGPS is designed to allow surgeons to decide where to remove bone and place the implant in the optimal position. Exactech first introduced ExactechGPS to surgeons in the United States for total knee arthroplasty, and has since broadened its reach to the shoulder segment. The technology has steadily gained market acceptance and worldwide reach.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

EN
29/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exactech, Inc.

 PRESS RELEASE

Exactech Announces Completion of Merger with TPG Capital

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech, Inc. (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, is pleased to announce the successful completion of the previously announced merger agreement with TPG Capital, pursuant to which TPG has acquired all of the issued and outstanding common stock of Exactech. In connection with the transaction, Exactech shareholders will receive $49.25 in cash for each share of Exactech common stock they hold (o...

 PRESS RELEASE

Exactech Shareholders Approve Merger Agreement with TPG Capital

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, today announced that at a Special Meeting of Shareholders held earlier today, Exactech’s shareholders approved the previously announced merger agreement with TPG Capital and certain of its affiliates, and approved the other two proposals described in Exactech’s proxy statement relating to today’s meeting. Approximately 94.5% of voting Exact...

 PRESS RELEASE

EXACTECH (EXAC) INVESTOR ALERT - Andrews & Springer LLC is Seeking Mor...

WILMINGTON, Del.--(BUSINESS WIRE)-- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Exactech, Inc. (NASDAQGS: EXAC) (“Exactech” or the “Company”) relating to the sale of the Company to affiliates of private equity firm TPG Capital (“TPG”). On December 4, 2017, the two parties announced the signing of an amended merger agreement pursuant to which TPG will acquire Exacte...

 PRESS RELEASE

EXACTECH (EXAC) SHAREHOLDER ALERT - Andrews & Springer LLC is Seeking ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Exactech, Inc. (NASDAQGS: EXAC) (“Exactech” or the “Company”) relating to the sale of the Company to affiliates of private equity firm TPG Capital (“TPG”). On December 4, 2017, the two parties announced the signing of an amended merger agreement pursuant to which TPG will acquire Exacte...

 PRESS RELEASE

Exactech Announces Successful First Surgery with Vantage ® Total Ankl...

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, hip, and knee, announced today the successful first surgery using its new Vantage® Total Ankle Mobile Bearing System, the newest addition to the Exactech extremities product line. Orthopaedic surgeon and Vantage Ankle design team member Professor Victor Valderrabano, MD, PhD, chairman of the Swiss Ortho Center Basel, recently performed the first case in the world with the mobile, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch